Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses

Journal of Clinical Oncology

Volumn 24, Issue 19, 2006, Pages 3164-3171

  Moschos, Stergios J ^b   Edington, Howard D ^b   Land, Stephanie R ^b   Rao, Uma N ^b   Jukic, Drazen ^b   Shipe Spotloe, Janice ^b   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CD11 ANTIGEN; CD3 ANTIGEN; MELANOMA ANTIGEN 1; TOLL LIKE RECEPTOR 3; ANTINEOPLASTIC AGENT; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER INFILTRATION; CANCER REGRESSION; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIVER TOXICITY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT RESPONSE; TUMOR BIOPSY; ADJUVANT THERAPY; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INTERFERON ALFA-2B; LYMPH NODE EXCISION; LYMPHOCYTE SUBSETS; MALE; MELANOMA; MIDDLE AGED; NEOADJUVANT THERAPY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33745989541     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.2498     Document Type: Article

References (28)

1. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
2. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 193:377-388, 1981
3. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
4. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996
5. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000
6. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
7. Lesinski GB, Anghelina M, Zimmerer J, et al: The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 112:170-180, 2003
8. Astsaturov I, Petrella T, Bagriacik EU, et al: Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: Implications for cancer vaccines. Clin Cancer Res 9:4347-4355, 2003
9. Kirkwood JM, Richards T, Zarour HM, et al: immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: The E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95:1101-1112, 2002
10. Gogas H, Paterakis G, Frangia K, et al: Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B. Am J Clin Oncol 25:591-596, 2002
11. Estevez LG, Gradishar WJ: Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 10:3249-3261, 2004
12. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003
13. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 359:1727-1733, 2002
14. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
15. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
16. Oh JL, Vokes EE, Kies MS, et al: Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 14:564-569, 2003
17. Ciriaco P, Rendina EA, Venuta F, et al: Preoperative chemotherapy and immunochemotherapy for locally advanced stage IIIA and IIIB non small cell lung cancer: Preliminary results. Eur J Cardiothorac Surg 9:305-309, 1995
18. Mantz CA, Vokes EE, Stenson K, et al: Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J 7:140-148, 2001
19. Temeck BK, Liebmann JE, Theodossiou C, et al: Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma. Cancer 77:2432-2439, 1996
20. Buzaid AC, Colome M, Bedikian A, et al: Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 8:549-556, 1998
21. Gibbs P, Anderson C, Pearlman N, et al: A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer 94:470-476, 2002
22. Su YB, Sohn S, Krown SE, et al: Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J Clin Oncol 22:610-616, 2004
23. Kirkwood JM, Ernstoff MS, Davis CA, et al: Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 103:32-36, 1985
24. Serpell JW, Carne PW, Bailey M: Radical lymph node dissection for melanoma. ANZ J Surg 73:294-299, 2003
25. Mihm MC Jr, Clemente CG, Cascinelli N: Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74:43-47, 1996
26. Hakansson A, Gustafsson B, Krysander L, et al: Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 74:670-676, 1996
27. Hakansson A, Gustafsson B, Krysander L, et al: Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res 18:33-39, 1998
28. Luft T, Luetjens P, Hochrein H, et al: IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol 14:367-380, 2002